Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Palliative focus needed in skilled nursing facilities

US data suggest that use of Medicare benefit for skilled nursing facilities is high during the last 6 months of life, highlighting a need to incorporate quality palliative care services in nursing homes, suggest researchers.

4 Oct 2012

Routine screening influences outcomes in prostate cancer after surgery

Men who undergo radical prostatectomy for a tumor that was detected by screening show better long-term outcomes than their peers who undergo the surgery after opportunistic diagnosis, study results show.

3 Oct 2012

ASTRO selects Boston-area resident as 2012 Survivor Circle Award winner

The American Society for Radiation Oncology (ASTRO) has selected Boston-area resident and prostate cancer survivor Emanuel "Manny" Hamelburg as its 2012 Survivor Circle Award winner.

3 Oct 2012

Adjuvants underused initially, follow up needed for cancer patients in pain

Italian study results indicate that physicians underuse adjuvant therapies for treatment of pain in cancer in the first instance, and that close follow up of oncology patients is needed to improve the efficacy of analgesic therapy in this setting.

2 Oct 2012

Genetic profile predicts postradiation erectile dysfunction

Scientists have identified a group of genetic markers that can predict the risk for erectile dysfunction after radiotherapy for prostate cancer.

1 Oct 2012

Active Biotech, Ipsen announce new data on biomarkers from tasquinimod Phase II study in CRPC

Active Biotech and Ipsen have presented a new set of data on biomarkers from the previously concluded tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific congress ESMO (European Society for Medical Oncology) held in Vienna September 28-October 2.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

September issue of JNCCN publishes two prostate cancer articles

Julio M. Pow-Sang, M.D., chair of Moffitt Cancer Center's Department of Genitourinary Oncology, and colleagues have published two prostate cancer articles in the September issue of JNCCN - The Journal of the National Comprehensive Cancer Network. The articles review and clarify recent updates made to the National Comprehensive Cancer Network's (NCCN) guidelines for the screening and treatment of prostate cancer.

29 Sep 2012

Mount Sinai surgeon offers tips to prevent prostate cancer

World-renowned Mount Sinai robotic prostate surgeon, Dr. David Samadi, devotes much of his time to prostate cancer education domestically and internationally. "My SMART robotic prostate removal surgery saves lives, but what men really want to know is how to prevent prostate cancer in the first place," shares Dr. Samadi.

29 Sep 2012

ACS honors world-leader in robotic prostate surgery with 2012 Community Partner Award

At last night's Annual Prostate Cancer Awareness and Education Dinner, the American Cancer Society awarded Dr. David B. Samadi, world-leader in prostate cancer treatment and robotic prostate surgery, with the 2012 Community Partner Award. Through robotic surgery excellence, Dr. Samadi has successfully cured more than 4,000 men of prostate cancer.

29 Sep 2012

First Edition: September 28, 2012

Today's headlines include reports about political and policy-oriented health care developments.

28 Sep 2012

Contrast-enhanced ultrasound effective in diagnosing men with high-grade prostate cancer

Contrast-enhanced ultrasound was found to better detect high-grade prostate cancer than conventional methods, making it a more appropriate approach for screening clinically important cancers and monitoring low-risk ones with less biopsies, researchers from Thomas Jefferson University and Hospitals conclude in a phase III study published online in September in the Journal of Urology.

28 Sep 2012

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

OncoGenex commences custirsen Phase 3 trial in non-small cell lung cancer

OncoGenex Pharmaceuticals, Inc. announced today the initiation of ENSPIRIT, a Phase 3 trial evaluating custirsen for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed after initial chemotherapy treatment has failed.

28 Sep 2012

Scientists discover 12 genetic markers for ED in prostate cancer patients after radiotherapy

In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.

27 Sep 2012

Henry Ford Hospital opens new Center for Cancer Surgery

With more patients seeking cancer treatment – especially surgery – than ever before, Henry Ford Hospital has opened the new Center for Cancer Surgery.

27 Sep 2012

Increasing doses of radium chloride effective, tolerated in prostate cancer

Radium chloride treatment has dose-dependent beneficial effects on health outcomes in patients with castration-resistant prostate cancer and bone metastases, report researchers.

26 Sep 2012

The ABC of terminal hemorrhage management

To best cope with terminal hemorrhage, at-risk patients should be identified by healthcare professionals while their families and caregivers are prepared, supported, and instructed to assure, be there for, and calm and comfort the patient as the event occurs, say researchers.

26 Sep 2012

Armband labeling could prevent DNR confusion

Implementation of an electronic ordering and armband labeling process for patients with Do Not Resuscitate orders improved correct documentation of their wishes as well as physicians’ ability to recognize and act on them during a cardiac arrest scenario, report US researchers.

25 Sep 2012